関連する実験動画
Updated: Apr 13, 2026

09:05
Minimal Invasive Surgical Procedure of Inducing Myocardial Infarction in Mice
Published on: May 4, 2015
29.1K
急性STセグメント上昇性心筋梗塞におけるインスリンによる抗炎症およびプロフィブリノリチス効果
Ajay Chaudhuri1, David Janicke, Michael F Wilson
1Division of Endocrinology, Diabetes and Metabolism, State University of New York at Buffalo, and Kaleida Health, Buffalo, NY 14209, USA.
Circulation
|February 6, 2004
まとめ
STセグメント上昇心筋梗塞 (STEMI) 患者に対するインスリン投与は,有意な抗炎症およびプロフィブリノリート効果を示した. これらの発見は,インスリンがインスリンであることを示唆しています.
科学分野:
- 心臓病学 心臓病学
- バイオケミストリー バイオケミストリー
- 薬理学 薬理学とは
背景:
- 急性STセグメント上昇心筋梗塞 (STEMI) のインスリンによる臨床的利益には,抗炎症メカニズムが含まれている可能性があります.
- この研究では,フィブリノリチック療法を受けているSTEMI患者におけるインスリンの抗炎症的可能性を調査した.
研究 の 目的:
- 急性STセグメント上昇心筋梗塞 (STEMI) 患者のインスリンによる抗炎症およびプロフィブリノリチス効果を評価する.
主な方法:
- レテプラスで治療を受けた32人のSTEMI患者は,ランダムにインスリン,デクストロース,およびカリウム (GIK) または通常の塩分とカリウム (コントロール) を48時間投与されました.
- 炎症のプラズママーカー (高感度C反応性タンパク質,血清アミロイドA) と凝固 (プラズミノゲン活性化剤阻害剤-1) を連続的に測定した.
- 単核細胞のp47phoxタンパク質レベルは,サブグループで評価されました.
主要な成果:
- インスリン治療は,対照群と比較して24時間および48時間で,C反応性タンパク質 (CRP) と血清アミロイドA (SAA) の上昇をそれぞれ40%および50%大幅に弱めた.
- インスリンがプラズミノゲン活性化剤阻害剤-1 (PAI-1) とp47phoxタンパク質濃度の上昇を著しく減少させた.
- クレアチンキナーゼ-MB (CK-MB) は,より早くピークに達し,インスリン群では,特に下位MI症例では,より低い傾向がありました.
結論:
- インスリンは,急性心筋梗塞 (MI) の患者において,抗炎症およびプロフィブリノリチス作用を示す.
- これらの観察されたインスリン効果は,STEMI管理における臨床的利点に寄与する可能性があります.
関連する概念動画
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
905
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
905
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Myocarditis I: Introduction
612
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
612
Myocarditis III: Medical Management
327
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
327
Acute Coronary Syndrome I: Introduction
1.8K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.8K
Acute Coronary Syndrome IV: Interprofessional Care
490
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
490

